Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Parp Inhibitors for Cancer Therapy

by Nicola J. Curtin
Save 35% Save 35%
Current price ₹10,900.00
Original price ₹16,769.00
Original price ₹16,769.00
Original price ₹16,769.00
(-35%)
₹10,900.00
Current price ₹10,900.00

Imported Edition - Ships in 18-21 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Hardcover
  • ISBN13: 9783319141503
  • Binding: Hardcover
  • Subject: N/A
  • Publisher: Springer
  • Publisher Imprint: Humana
  • Publication Date:
  • Pages: 591
  • Original Price: EUR 149.99
  • Language: English
  • Edition: 2015
  • Item Weight: 1026 grams
  • BISAC Subject(s): Oncology / General, Pharmacology, and Life Sciences / Molecular Biology

From the Back Cover

PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP--poly ADP ribose polymerase--in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors.

PARP inhibitors--PARPi--are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The "synthetic lethality" of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.

Nicola Jane Curtin, Ph.D. is Professor of Experimental Cancer Therapeutics at Newcastle University. Dr. Curtin is also the team leader for DNA damage signalling and repair projects within CR-UK Drug Development Programme.

Ricky Sharma is Associate Professor at the University of Oxford and Honorary Consultant in Clinical Oncology at the Oxford University Hospitals NHS Trust. He graduated in medicine from the University of Cambridge, and subsequently trained in toxicology, general internal medicine, medical oncology and clinical oncology in Cambridge, Glasgow, Leicester and London. Since 2006, he has led a translational research group at the University of Oxford focussed on DNA damage repair and the development of new chemotherapy and radiotherapy treatments for cancer.

Trusted for over 49 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us